Recombinant Human KEAP1 cell lysate

• Cat.No.: KEAP1-001HCL
• Product Overview: Human KEAP1 / INRF2 derived in Baculovirus-Insect cells. The whole cell lysate is provided in 1X Sample Buffer.Browse all transfected cell lysate positive controls

Specification

• Source: Baculovirus-Insect Cells
• Species: Human
• Preparation method: Transfected cells were cultured for 48hrs before collection. The cells were lysed in modified RIPA buffer with cocktail of protease inhibitors. Cell debris was removed by centrifugation and then centrifuged to clarify the lysate. The cell lysate was boiled for 5 minutes in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% b-mercaptoethanol, and lyophilized.
• Lysis buffer: Modified RIPA Lysis Buffer: 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% SDS, 1% Sodium deoxycholate, 1mM PMSF
• Quality control Testing: 12.5% SDS-PAGE Stained with Coomassie Blue
• Recommended Usage: 1. Centrifuge the tube for a few seconds and ensure the pellet at the bottom of the tube.2. Re-dissolve the pellet using 200μL pure water and boiled for 2-5 min.3. Store it at -80°C. Recommend to aliquot the cell lysate into smaller quantities for optimal storage. Avoid repeated freeze-thaw cycles.Notes:The lysate is ready to load on SDS-PAGE for Western blot application. If dissociating conditions are required, add reducing agent prior to heating.
• Stability: Samples are stable for up to twelve months from date of receipt at -80°C
• Storage Buffer: 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% SDS, 1% Sodium deoxycholate, 1mM PMSF
• Storage Instruction: Lysate samples are stable for 12 months from date of receipt when stored at -80°C. Avoid repeated freeze-thaw cycles. Prior to SDS-PAGE fractionation, boil the lysate for 5 minutes.

Gene Information

• Gene Name: KEAP1 kelch-like ECH-associated protein 1 [ Homo sapiens ]
• Official Symbol: KEAP1
• Synonyms: KEAP1; kelch-like ECH-associated protein 1; INrf2; KIAA0132; KLHL19; MGC1114; MGC4407; MGC9454; MGC10630; MGC20887; kelch-like protein 19; cytosolic inhibitor of Nrf2
• Gene ID: 9817
• mRNA Refseq: NM_012289
• Protein Refseq: NP_036421
• MIM: 606016
• UniProt ID: Q14145
• Chromosome Location: 19p13.2
• Pathway: Adaptive Immune System, organism-specific biosystem; Antigen processing: Ubiquitination and Proteasome degradation, organism-specific biosystem; Class I MHC mediated antigen processing & presentation, organism-specific biosystem; Immune System, organism-specific biosystem; Keap1-Nrf2 Pathway, organism-specific biosystem
• Function: protein binding

Reviews

01/02/2023

This protein demonstrates exceptional performance in ELISA, delivering accurate and reliable results in the detection and quantification of specific antigens.

06/29/2016

KEAP1 protein has proven to be instrumental in protein electron microscopy structure analysis.

04/07/2016

With KEAP1 protein, researchers can visualize protein complexes and their interactions with remarkable clarity, unraveling important insights into their functional mechanisms.

Q&As

How does KEAP1 function in the body's defense against oxidative stress?

KEAP1 acts as a sensor for oxidative stress by interacting with NRF2. When cells experience oxidative stress, KEAP1 releases NRF2, allowing it to translocate into the nucleus and initiate the expression of various cytoprotective genes.

How is the interaction between KEAP1 and NRF2 regulated within cells?

Post-translational modifications such as phosphorylation, ubiquitination, and acetylation control the interaction between KEAP1 and NRF2, influencing NRF2's stability and activity.

Are there any challenges in targeting KEAP1 for therapeutic interventions?

One challenge is the need for specific targeting without causing adverse effects on normal cell function, as NRF2 has both protective and potentially harmful effects.

In what other ways can the KEAP1 protein be targeted for therapeutic purposes?

Researchers are exploring small molecules that modulate the KEAP1-NRF2 interaction, aiming to enhance NRF2 activation for therapeutic benefit in conditions where oxidative stress plays a significant role.

Are there ongoing clinical trials involving KEAP1-related therapies?

Yes, there are clinical trials investigating drugs that target the KEAP1-NRF2 pathway in cancer treatment, especially for lung and pancreatic cancers.